锐达医药

Ouro Medicines是一家免疫重置公司，通过结合科学专业知识、通过临床推进细胞耗竭疗法的跟踪记录以及强大的管道来正面应对慢性免疫介导的疾病。Ouro最领先的候选产品是OM336，这是一种最近从康诺亚生物获得许可的BCMA靶向的双特异性TCE。

RhyGaze开发一种新的基因疗法，旨在恢复患者的视力。该公司的治疗技术将光传感器基因专门传递给失去光敏感性的视锥细胞，并修复其检测光的能力，使医疗保健行业能够为失明患者提供视力恢复。

Thetis Pharmaceuticals LLC is a pharmaceutical company focused on the development of prescription drugs for diabetes, hypertriglyceridemia and dyslipidemia. Thetis's proprietary HEALER technology (High Efficiency Amino Lipid Enabled Release) uses transformative ionic chemistry to revitalize proven therapeutic agents and generated solid, stable APIs.In July 2021, Thetis Pharmaceuticals LLC announced the launch of a new program in cancer TP-317, which is a Resolvin E1 therapy for the treatment of solid tumour cancers published in the Journal of Experimental Medicine.In May 2013, the company raised $5.7 million through a series A financing.In September 2011, Thetis secured first round funding. At that time, the company planned to secure additional capital in the second half of 2012